Renin-angiotensin system (ACEIs and/or ARBs) (versus unexposed) updated on 03-11-2025

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.66 [1.21, 2.30]69%14 studies29,8064,726critical ROB2.72 [1.70; .]
Major congenital malformations1.68 [1.21, 2.34]71%13 studies29,8024,618critical ROB2.76 [1.71; .]
Congenital heart defects2.17 [1.27, 3.72]80%9 studies14,2184,017serious ROB3.76 [1.85; .]
Coarctation of aorta3.76 [0.85, 16.59]19%2 studies98not evaluable ROB-
Atrial septal defect2.70 [1.44, 5.05]-1 study21not evaluable ROB4.84 [2.24; .]
Ebstein's anomaly26.40 [2.29, 304.51]-1 study654not evaluable ROB52.30 [4.01; .]
Hypospadias1.23 [0.43, 3.50]8%2 studies2,13165not evaluable ROB-
Nervous system anomalies1.46 [0.19, 11.38]89%2 studies832,840not evaluable ROB-
Urinary malformations4.01 [1.39, 11.58]3%3 studies5548not evaluable ROB7.48 [2.12; .]
Genital anomalies5.73 [2.64, 12.42]0%2 studies5130not evaluable ROB10.93 [4.72; .]
Ventricular septal defect6.91 [1.43, 33.35]-1 studynot evaluable ROB13.30 [2.22; .]
Chromosomal abnormalities14.76 [3.64, 59.81]-1 study84not evaluable ROB29.01 [6.74; .]
Down syndrom / Trisomy 219.56 [2.20, 41.59]-1 study84not evaluable ROB18.61 [3.82; .]
6 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)2.83 [2.04, 3.94]71%8 studies38,6561,267not evaluable ROB5.11 [3.49; .]
Small for gestational age (weight)2.05 [1.21, 3.49]0%4 studies8,156222not evaluable ROB3.52 [1.71; .]
Low birth weight (< 2500g)2.39 [1.71, 3.34]48%3 studies27,5331,318not evaluable ROB4.21 [2.82; .]
Very preterm (28 to 32 weeks)3.40 [1.04, 11.15]-1 study12942not evaluable ROB6.26 [1.23; .]
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean2.01 [1.62, 2.50]0%2 studies2,681159not evaluable ROB3.43 [2.61; .]
Preeclampsia2.08 [0.82, 5.27]62%2 studies256782not evaluable ROB-
3 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Fetal distress--0 study-
Jaundice / Icterus2.66 [1.51, 4.68]-1 study7,60584not evaluable ROB4.76 [2.39; .]
Neonatal medical care--0 study-
4 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions1.41 [1.07, 1.84]6%6 studies5161,128not evaluable ROB2.16 [1.35; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths2.13 [0.84, 5.42]0%6 studies871,086not evaluable ROB-
Elective/induced termination of pregnancy2.80 [1.42, 5.52]66%5 studies1941,068not evaluable ROB5.05 [2.19; .]
Therapeutic terminations of pregnancy4.65 [1.41, 15.33]0%3 studies27382not evaluable ROB8.76 [2.17; .]
1 non statistically significant endpoints reported in only one study

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons